Similarly, an A2AR homodimer-disrupting construct, efficiently delivered by a protease-resistant cyclic CPP, was designed and produced for in vivo studies on the A2AR-A2AR homodimer implication in CNS disorders, including schizophrenia and Parkinson’s disease. This evidence concerns the gene ADORA2A and Parkinson disease.